Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chubb
Covington
Deloitte
Farmers Insurance
Cantor Fitzgerald
Fish and Richardson
Teva
Merck

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,716,830

« Back to Dashboard

Which drugs does patent 6,716,830 protect, and when does it expire?

Patent 6,716,830 protects MOXEZA and VIGAMOX and is included in two NDAs.

Protection for MOXEZA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-two patent family members in nineteen countries.
Summary for Patent: 6,716,830
Title: Ophthalmic antibiotic compositions containing moxifloxacin
Abstract:Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
Inventor(s): Cagle; Gerald (Fort Worth, TX), Abshire; Robert L. (Fort Worth, TX), Stroman; David W. (Irving, TX), Yanni; John M. (Burleson, TX)
Assignee: Alcon, Inc. (Hunenberg, CH)
Application Number:10/200,868
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,716,830
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 6,716,830

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 AT2 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp VIGAMOX moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 021598-001 Apr 15, 2003 AT1 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,716,830

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,740,664 Methods for treating otic and ophthalmic infections ➤ Try a Free Trial
8,673,902 Method of treating otic infections with moxifloxacin compositions ➤ Try a Free Trial
8,993,636 Compositions containing moxifloxacin for treating otic infections ➤ Try a Free Trial
6,395,746 Methods of treating ophthalmic, otic and nasal infections and attendant inflammation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,716,830

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 020661 ➤ Try a Free Trial
Argentina 081393 ➤ Try a Free Trial
Austria 254458 ➤ Try a Free Trial
Austria 501732 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
Baxter
Colorcon
Fish and Richardson
Covington
Cipla
Moodys
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.